Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-06-12
2007-06-12
Kaushal, Sumesh (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S069100, C435S325000, C435S455000
Reexamination Certificate
active
10261188
ABSTRACT:
The present invention relates to methods and compositions for increasing the production of high titre stocks of recombinant AAV (rAAV) through regulation of expression of the AAV REP and CAP proteins. The methods and compositions of the invention are based on the observation that the low level expression of the AAV REP protein increases the production of AAV viral capsid protein and efficiency of packaging resulting in production of higher titre recombinant viral stocks. The invention encompasses recombinant AAV vectors that direct the expression of AAV REP and CAP proteins and the use of such vectors for the production of novel stable cell lines capable of generating high titre rAAV vectors. The invention provides methods for regulating the expression of the AAV REP gene at the transcriptional and post-translational level. The methods and compositions of the invention can be used to produce high titre stocks of rAAV which can be used in gene therapy for the purpose of transferring genetic information into appropriate host cells for the management and correction of human diseases including inherited and acquired disorders.
REFERENCES:
patent: 4797368 (1989-01-01), Carter et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5622856 (1997-04-01), Natsoulis
patent: 5753500 (1998-05-01), Shenk et al.
patent: 6001650 (1999-12-01), Colosi
patent: 6027931 (2000-02-01), Natsoulis et al.
patent: 6037177 (2000-03-01), Snyder
patent: 6365403 (2002-04-01), Natsoulis et al.
patent: 6548286 (2003-04-01), Samulski et al.
patent: WO 88/04300 (1988-06-01), None
patent: WO 90/11364 (1990-10-01), None
patent: WO 95/14771 (1995-06-01), None
patent: WO 97/09441 (1997-03-01), None
Yang et al J. Virol. 66(10):6058-6069, 1992.
Holscher et al J Virol. 69(11):6880-6885, 1995.
Xiao et al. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 72(3):2224-32, 1998.
Allen et al. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol. Sep. 1997;71(9):6816-22.
Antoni et al., 1991, “Adeno-Associated Virus Rep Protein Inhibits Human Immunodeficiency Virus Type 1 Production in Human Cells”, J. Virol. 65:396-404.
Bank et al., “Gene Transfer: A Potential Approach to Gene Therapy for Sickle Cell Disease”, Annals NY Acad of Sciences, pp. 37-43.
Been and Cech , 1986, “One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity”, Cell 47:207-16.
Berns et al., 1982, Virus Persistence, eds. Mahey, BWJ, et al., Cambridge Univ. Press., pp. 249-265.
Beutler et al., 1990, “Gene Transfer in the Treatment of Hematologic Disease”, Exp. Hematol. 18:857-860.
Bosselman et al., “Replication-Defective Chimeric Helper Proviruses and Factors Affecting Generation of Competent Virus: Expression of Moloney Murine Leukemia Virus Structural Genes Via the Metallothionein Promoter”, Mol. Cell Biol. 7:1979-1806.
Brinster et al., 1982, “Regulation of metallothionein—thymidine kinase fusion plasmids injected into mouse eggs”, Nature 296:39-42.
Chang et al., 1992, “A 36 base pair core sequence of locus of control region enhances retrovirally transferred human β globin gene expression”, PNAS USA 89:3107-110.
Chejanovsky and Carter, 1989, “Mutagenesis of an AUG Codon in the Adeno-Associated VirusrepGene: Effects on Viral DNA Replication”, Virol. 173: 120-128.
Cheung et al., 1980, “Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells.”, J. Virol. 33:739-48.
de la Maza LM et al. Molecular structure of adeno-associated virus variant DNA. J Biol Chem. Apr. 10, 1980;255(7):3194-203.
Desnick et al., 1991, “Human Gene Therapy: Strategies and Prospects for Inborn Errors of Metabolism”, Treatment for Genetic Diseases, pp. 239-259.
Figge et al., 1988, “lacRepressor Can Regulate Expression from a Hybrid SV40 Early Promoter Containing alacOperator in Animal Cells”, Cell 49:603-12.
Flotte et al., 1995, “An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction.” Gene Therapy. 2:29-37.
Flotte TR and Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther. Aug. 1995;2(6):357-62. Review.
Friedmann, “Gene Therapy”, Therapy for Genetic Disease, pp. 107-121.
Gorman et al., 1989, “The human cytomegalovirus major immediate early promoter can be trans-activated by adenovirus early proteins.”, Virology 171:377-385.
Guatier et al., 1987, “Alpha-DNA. IV: Alpha-anomeric and beta-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding”, .Nucl Acid Res. 15:6625-6641.
Heilbronn et al., 1990, “The Adeno-Associated VirusrepGene Suppresses Herpes Simplex Virus-Induced DNA Amplification”, J. Virol. 64:3012-3018.
Hermonat, 1994, “Down-Regulation of the Humanc-fosandc-mycProto-Oncogene Promoters by Adeno-Associated Virus Rep78”, Cancer Lett. 81:129-136.
Hermonat et al., 1984, “Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells”, PNAS USA 81:6466-6670.
Hirt et al., 1967, “Selective extraction of polyoma DNA from infected mouse cell cultures”, J. Mol. Biol. 26:365-369.
Horer et al., 1995, “Mutational Analysis of Adeno-Associated Virus Rep Protein-Mediated Inhibition of Heterologous and Homologous Promoters”, J. Virol. 69:5485-5496.
Hu et al., 1987, “The inducible lac operator-repressor system is functional in mammalian cells”, Cell 48:555-566.
Hunter et al., 1992, “Colocalization of adeno-associated virus Rep and capsid proteins in the nuclei of infected cells”, J Virology 66:317-324.
Inoue et al., 1987, “Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H”, FEBS Lett. 215:327-330.
Inoue et al., 1987. “Synthesis and hybridization studies on two complimentary nona(2′-O-methyl)ribonucleotides”, Nucl Acids Res. 15:6131-6148.
Koeberl et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A. Feb. 18, 1997;94(4):1426-31.
Kotin et al., 1994, “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy”, Human Gene Therapy 5:793-801.
Kotin et al., 1990, “Site-specific integration by adeno-associated virus”, Proc Natl Acad Sci U S A. 87(6):2211-2215.
Labow et al., 1986, “Positive and negative autoregulation of the adeno-associated virus type 2 genome.” J. Virol. 60:251-258.
Labow et al., 1988, “The adeno-associated virus rep gene inhibits replication of an adeno-associated virus/simian virus 40 hybrid genome in cos-7 cells”, J. Virol. 62:1705-1712.
Labow et al., 1987, “Adeno-Associated Virus Gene Expression Inhibits Cellular Transformation by Heterologous Genes”, Mol. Cell. Biol. 7:1320-1325.
LaFace et al., 1988, “Gene Transfer into Hematopoietic Pregenitor Cells Mediated by an Adeno-Associated Virus Vector”, Virology 162:483-6.
Laughlin et al., 1982, “Effect of deletions in adenovirus early region 1 genes upon replication of adeno-associated virus.”, J. Virology 41:868-876.
Laughlin et al., 1983, “Cloning of Infectious Adeno-Associated Virus Genomes in Bacterial Plasmids”, Gene 23:65-73.
Lebkowski et al., “Adeno-Associated Virus: A Vector System for Efficient Introduction and Integration of DNA into a Variety of Mammalian Cell Types”, Mol. Cell. Biol., 8:3988-3996.
Ledley, 1991
Samulski Richard Jude
Snyder Richard
Xiao Xiao
LandOfFree
Methods for increasing the efficiency of recombinant AAV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for increasing the efficiency of recombinant AAV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for increasing the efficiency of recombinant AAV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3817246